...
首页> 外文期刊>Frontiers in Medicine >Clinical Features, Diagnosis, and Treatment of COVID-19 in Hospitalized Patients: A Systematic Review of Case Reports and Case Series
【24h】

Clinical Features, Diagnosis, and Treatment of COVID-19 in Hospitalized Patients: A Systematic Review of Case Reports and Case Series

机译:住院患者Covid-19的临床特征,诊断和治疗:案件报告和案例系列的系统审查

获取原文
   

获取外文期刊封面封底 >>

       

摘要

Introduction: The 2019 novel coronavirus (COVID-19) has been declared a public health emergency worldwide. The objective of this systematic review was to characterize the clinical, diagnostic, and treatment characteristics of hospitalized patients presenting with COVID-19. Methods: We conducted a structured search using PubMed/Medline, Embase, and Web of Science to collect both case reports and case series on COVID-19 published up to April 24, 2020. There were no restrictions regarding publication language. Results: Eighty articles were included analyzing a total of 417 patients with a mean age of 48 years. The most common presenting symptom in patients who tested positive for COVID-19 was fever, reported in up to 62% of patients from 82% of the analyzed studies. Other symptoms including rhinorrhea, dizziness, and chills were less frequently reported. Additionally, in studies that reported C-reactive protein (CRP) measurements, a large majority of patients displayed an elevated CRP (60%). Progression to acute respiratory distress syndrome (ARDS) was the most common complication of patients testing positive for COVID-19 (21%). CT images displayed ground-glass opacification (GGO) patterns (80%) as well as bilateral lung involvement (69%). The most commonly used antiviral treatment modalities included, lopinavir (HIV protease inhibitor), arbidiol hydrochloride (influenza fusion inhibitor), and oseltamivir (neuraminidase inhibitor). Conclusions: Development of ARDS may play a role in estimating disease progression and mortality risk. Early detection of elevations in serum CRP, combined with a clinical COVID-19 symptom presentation may be used as a surrogate marker for the presence and severity of the disease. There is a paucity of data surrounding the efficacy of treatments. There is currently not a well-established gold standard therapy for the treatment of diagnosed COVID-19. Further prospective investigations are necessary.
机译:简介:2019年新型冠状病毒(Covid-19)已在全球宣布公共卫生紧急情况。该系统审查的目的是表征住院治疗患者的临床,诊断和治疗特征,患有Covid-19。方法:我们使用PubMed / Medline,Embase和Science进行了结构化搜索,并在2020年4月24日公布的Covid-19上收集案例报告和案例系列。没有关于出版物语言的限制。结果:八十篇文章分析了417名患者,平均年龄为48岁。测试Covid-19发烧阳性的患者中最常见的呈现症状,据报道,患者的82%的分析研究中有62%。据报道,其他症状包括鼻肠,头晕和寒冷。另外,在报告的C反应蛋白(CRP)测量的研究中,大多数患者均显示升高的CRP(60%)。急性呼吸窘迫综合征(ARDS)的进展是患者对Covid-19(21%)阳性的最常见的并发症。 CT图像显示底玻璃透露(GGO)模式(80%)以及双侧肺参与(69%)。最常用的抗病毒治疗方式包括,洛诺维尔(HIV蛋白酶抑制剂),盐酸阿匹啶醇(流感融合抑制剂)和Oseltamivir(神经氨酸酶抑制剂)。结论:ARDS的发展可能在估算疾病进展和死亡率风险方面发挥作用。早期检测血清CRP中的升高,与临床covid-19的症状呈现相结合,可以用作蛋白质的存在和严重程度的替代标志物。既缺乏治疗疗效的数据。目前没有良好的金标准治疗,用于治疗诊断的Covid-19。进一步的预期调查是必要的。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号